SOURCE: BioTech Medics, Inc.

June 23, 2006 11:18 ET

BioTech Medics, Inc. Has Contracted for Tests of Patented SHBAN Solution as Proven Avian Bird Flu Virus Anti-Viral Disinfectant

DALLAS, TX -- (MARKET WIRE) -- June 23, 2006 -- BioTech Medics, Inc. (PINKSHEETS: BTMD) announced today that it has contracted with Retroscreen Virology, at the University of London, Queen Mary's School of Medicine, London to conduct a study to determine the efficacy of viricidal SHBAN against Avian HSN1 Influenza NIBRG-14 Virus (also known as the Avian Bird Flu).

"We are confident that the SHBAN solution has anti-viral properties that will kill the Avian Influenza virus upon contact without harming humans, animals and the environment," said Delton Carroll, President & CEO of FHJ Scientific and Advisor to BioTech Medics. "SHBAN has previously been tested by Baylor Medical Center in Houston, Louisiana State University, UT Houston, Allergan, Pathology Associates, MBA Labs and Texas A&M College of Veterinary Medicine. SHBAN has tested to be a safe germicidal cleaning solution."

The clear superiority of SHBAN over other disinfectants is that SHBAN is long lasting, it does not evaporate within one minute after application; it is non-toxic (when used as directed), it is non-staining, non-bleaching, and has no harmful or toxic odors.

Upon successful completion of testing, the SHBAN solution will be sold in various forms such as SHBAN Hand Sanitizer or licensed out to be a hand sanitizer additive ingredient and SHBAN Fogger Mist to cover large areas. SHBAN Mister Solution will also be sold to sanitize infected poultry buildings and wildlife areas which are potential areas for contamination with Avian Influenza. BioTech is also considering selling a SHBAN Cat Litter additive. SHBAN should be considered for preventive measures to spray non-infected areas. SHBAN is protected under US Letters of Patent #4,868,213, #5,514.808, #5,574,050, #5,679,711 5,679 and #5,585,391 and several EU and other foreign patents.

BioTech Medics will provide SHBAN samples to government or world health officials should they desire to independently test the SHBAN solution.

The SHBAN™ solution, in previous in vitro and in vivo testing, has been evaluated for its antimicrobial properties against S. Aureus, S. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Tests revealed that SHBAN was extremely effective against all species of bacteria that were tested. Bacterial counts of the test models were reduced to < 100 bacteria per gram of tissue in the treated groups, while bacteria counts remained at 6 x 10/5 CFU/GM over 14 days in the untreated control groups.

Safe Harbor: Forward-Looking Statements.

This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, the words "plan," "confident that," "believe" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks, uncertainties and results could differ materially from those expressed in the forward-looking statements.

The statements above have not been evaluated by the FDA. The SHBAN product mentioned is not intended to diagnose, treat or cure any disease.

Contact Information

  • Contact:
    Keith Houser
    CEO
    Phone 972-274-5533